Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

Inclusion Criteria:

1. Aged 18-75 years;
2. Pathologically confirmed diagnosis of locally advanced colorectal cancer (cT3-4 and/or N+);
3. Planned to undergo neoadjuvant therapy followed by surgical resection;
4. No evidence of distant metastasis (M0) confirmed by imaging (CT and/or PET-CT);
5. Clinically assessed as being able to tolerate and complete the full course of neoadjuvant treatment;
6. No prior anti-tumor therapy (e.g., targeted therapy, immunotherapy) before the initiation of treatment;
7. Willing and able to provide urine samples as required;
8. Written informed consent obtained.

Exclusion Criteria:

1. History of or concurrent diagnosis with other malignancies;
2. Presence of severe hepatic, renal, cardiovascular, or metabolic diseases that may affect urinary protein metabolism;
3. Recent use of medications known to affect protein metabolism (e.g., glucocorticoids, high-dose antibiotics);
4. Urinary tract infection or other diseases known to cause abnormal urinary protein levels (e.g., nephrotic syndrome);
5. Any other condition deemed unsuitable for enrollment by the investigators.